替格瑞洛联合替罗非班在急性冠状动脉综合征PCI术后应用的临床疗效及安全性分析  

Clinical efficacy and safety analysis of ticagrelor combined with tirofiban in PCI after acute coronary syndrome

作　　者：朱永芝[1] 刘骏 ZHU Yong-zhi;LIU Jun(The First Department of Cardiology,Huaihua First People's Hospital,Huaihua 418000,China)

机构地区：[1]怀化市第一人民医院心内一科,湖南怀化418000

出　　处：《中国处方药》2021年第5期106-107,共2页Journal of China Prescription Drug

摘　　要：目的探讨替格瑞洛联合替罗非班在急性冠状动脉综合征PCI术后应用的临床疗效及安全性。方法选取2016年1月~2017年7月收治的130例急性冠脉综合征患者作为研究对象。按治疗方法将其分为对照组和观察组,每组65例。对照组PCI术后采取替格瑞洛抗血小板治疗,观察组PCI术后采取替格瑞洛联合替罗非班治疗,所有患者均治疗6个月。检测两组服药前和服药后24 h、48 h及6个月的血小板聚集率,记录6个月治疗期间的不良反应。结果服药前两组患者血小板抑制率差异无统计学意义(P>0.05)。两组服药后24 h、48 h及6个月血小板抑制率均明显增加(P<0.05),且观察组增加更为明显(P<0.05)。两组服药期间均未出现颅内出血和消化道出血。观察组发生牙龈出血、穿刺部位血肿及皮下出血共5例,不良反应发生率为7.69%;对照组共出现6例,不良反应发生率为9.23%;两组不良反应发生率差异无统计学意义(P>0.05)。观察组发生血管重建0例、严重心绞痛1例、心肌梗死3例及心源性死亡0例,总发生率为6.15%;对照组分别为1例、2例、4例及2例,总发生率为13.85%,两组不良心血管事件发生率差异有统计学意义(P<0.05)。结论替格瑞洛联合替罗非班在PCI患者血小板抑制率及减少心血管不良事件方面明显优于替格瑞洛单药治疗,且具有较高的安全性。Objective To investigate the clinical efficacy and safety of ticagrelor combined with tirofiban in PCI after acute coronary syndrome.Methods 130 patients with acute coronary syndrome admitted were selected as the research object from January 2016 to July 2017.According to the treatment method,the patients were divided into control group and observation group,65 cases in each group.The control group was treated with ticagrelor after PCI,and the observation group was treated with ticagrelor and tirofiban after PCI.All patients were treated for 6 months.The platelet aggregation rates of the two groups before and 24,48 hours and 6-month after taking the drug were detected,and the adverse reactions and cardiovascular adverse events during the 6-month treatment period were recorded.Results There was no statistically significant difference in platelet inhibition rate between the two groups before taking the drug(P>0.05).24,48 h and 6-month after taking the drug,the platelet inhibition rate of both groups increased significantly(P<0.05),and the increase in the observation group was more significant(P<0.05).There was no intracranial hemorrhage and gastrointestinal hemorrhage occurred during the medication in both groups.There were 5 cases of gum bleeding,hematoma at the puncture site and subcutaneous bleeding in the observation group and adverse reaction rate was 7.69%;6 cases in the control group,and adverse reaction rate was 9.23%;there was no statistical difference in the incidence of adverse reactions between the two groups(P>0.05).In the observation group,there were 0 cases of vascular remodeling,1 case of severe angina pectoris,3 cases of myocardial infarction and 0 cases of cardiogenic death,with a total incidence of 6.15%.There were 1 case,2 cases,4 cases and 2 cases in the control group,respectively,with a total incidence of 13.85%,and there was statistical significance in the incidence of adverse cardiovascular events between the two groups(P<0.05).Conclusion Ticagrelor combined with tirofiban is superior to tic

关 键 词：替格瑞洛 替罗非班 PCI 疗效 安全性 

分 类 号：R541.4[医药卫生—心血管疾病]